Institutional members access full text with Ovid®

Share this article on:

Transconjunctival Revision With Mitomycin-C Following Failed Trabeculectomy

Panarelli, Joseph F. MD; Vinod, Kateki MD; Huang, Gintien MD; Sidoti, Paul A. MD

doi: 10.1097/IJG.0000000000000408
Original Studies

Purpose: To evaluate the efficacy of transconjunctival revision (TCR) with mitomycin-C (MMC) following failed trabeculectomy.

Materials and Methods: The medical records of 27 patients (27 eyes) who underwent TCR with subconjunctival injection of MMC by a single surgeon between September 2001 and August 2013 were retrospectively reviewed. The same surgical protocol was followed for all patients. Revision was performed using a microvitreoretinal blade through a small conjunctival incision. Main outcome measures included visual acuity, intraocular pressure (IOP), and number of glaucoma medications. Failure was defined as an IOP<5 or >14 mm Hg, loss of light perception, or need for additional glaucoma surgery.

Results: Mean interval between trabeculectomy and TCR was 56.4±57.2 months. Mean preoperative IOP was 21.9±6.8 mm Hg using 4.0±1.2 glaucoma medications. Fifteen (55.6%) patients met success criteria. At most recent follow-up, mean IOP and number of glaucoma medications for successful patients were 9.7±3.8 mm Hg and 0.6±1.1, respectively. Kaplan-Meier analysis revealed 1-, 2-, and 3-year success rates of 62%, 58%, and 53%, respectively. Three additional patients achieved success after undergoing a second TCR, and 1 patient achieved success after a third TCR. Postoperative complications included transient choroidal effusion (n=8), shallow anterior chamber requiring reformation (n=5), 5-fluorouracil-related corneal epitheliopathy (n=10), and bleb leak (n=1).

Conclusions: TCR with adjunctive MMC is a safe and effective procedure following failure of a trabeculectomy. More than 1 revision may be necessary to achieve long-term IOP reduction.

Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai and Icahn School of Medicine at Mount Sinai, New York, NY

Presented in part at the American Glaucoma Society Annual Meeting, February, 2014.

P.A.S. is supported by grants from the David E. Marrus Glaucoma Research Fund and the Herman Peters Pediatric Glaucoma Research Fund.

Disclosure: The authors declare no conflict of interest.

Reprints: Kateki Vinod, MD, Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai and Icahn School of Medicine at Mount Sinai, 310 East 14th Street, Suite 603 South, New York, NY (e-mail:

Received June 15, 2015

Accepted February 2, 2016

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.